AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

⚠ The Direct Price Becomes the ReferenceLow threat

Gilead Sciences (GILD) — threat to the moat

Gilead's agreed direct-to-patient Epclusa price is small in revenue and large as a precedent.

The Epclusa direct-to-patient price agreed in December 20251 matters less for its own revenue, now $1,272 million a year2, than as a precedent. It shows Gilead accepting a price set in negotiation with the administration rather than with insurers.

Gilead Liver Disease sales, Q2 ($M)795Q2 2025877Q2 2026Gilead Q2 2026 results release; growth from Livdelzi, HBV and Hepcludex, not HCV
Liver Disease grew; hepatitis C inside it did not.

The same agreement extends most-favoured-nation pricing to Medicaid for select existing products and to the US market for future launches3. Each concession narrows the range within which Gilead can price new medicines.

There is no sign yet of the Epclusa terms spreading to HIV. But Gilead's 10-K already expects the Biktarvy Medicare price to lead to increased Medicaid rebates and lower 340B ceiling prices4, which is how one negotiated price propagates.

Hepatitis C is a reasonable place for such a precedent, because it is a cure sold to a shrinking pool. Sofosbuvir and velpatasvir sales were $1,596 million in 2024 and $1,272 million in 20255. A lower direct price may even raise volume. The risk lies in where the method goes next, not in Epclusa itself.

The tell would be any HIV product appearing on a future direct-to-patient or MFN list. One appearance before 2028 would mean the hepatitis C terms were the start of a pattern.

References
  1. ReportedThe Epclusa direct-to-patient price agreed in December 2025 matters less for its own revenue, now $1,272 million a year, than as a precedent.
    Gilead Sciences Form 10-Q for the quarter ended 30 June 2026 - acquired IPR&D for Arcellx, Tubulis and Ouro, the $1.75 billion Trodelvy impairment, debt, receivables and the December 2025 agreement with the US administration. — Q2 2026 · publ. 6 August 2026 · source ↗
  2. ReportedThe Epclusa direct-to-patient price agreed in December 2025 matters less for its own revenue, now $1,272 million a year, than as a precedent.
    Gilead Sciences Form 10-K for 2025 - revenue by product, product group and region (Note 2) and the MD&A discussion of product sales. — FY2025 · publ. 24 February 2026 · source ↗
  3. ReportedThe same agreement extends most-favoured-nation pricing to Medicaid for select existing products and to the US market for future launches.
    Gilead Sciences Form 10-Q for the quarter ended 30 June 2026 - acquired IPR&D for Arcellx, Tubulis and Ouro, the $1.75 billion Trodelvy impairment, debt, receivables and the December 2025 agreement with the US administration. — Q2 2026 · publ. 6 August 2026 · source ↗
  4. ReportedBut Gilead's 10-K already expects the Biktarvy Medicare price to lead to increased Medicaid rebates and lower 340B ceiling prices, which is how one negotiated price propagates.
    Gilead Sciences Form 10-K for 2025 - Item 1A risk factors and pricing regulation: the IRA, Medicare negotiation, Medicaid, the ACA and tariffs. — FY2025 · publ. 24 February 2026 · source ↗
  5. ReportedSofosbuvir and velpatasvir sales were $1,596 million in 2024 and $1,272 million in 2025.
    Gilead Sciences Form 10-K for 2025 - revenue by product, product group and region (Note 2) and the MD&A discussion of product sales. — FY2025 · publ. 24 February 2026 · source ↗
Sources
Generated October 4, 2026